Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study

• Published in: Headache Vol. 53; no. 10; pp. 1548 - 1563
• Main Authors: Lipton, Richard B., Serrano, Daniel, Nicholson, Robert A., Buse, Dawn C., Runken, M. Chris, Reed, Michael L.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.11.2013; Wiley Subscription Services, Inc
• Subjects: acute treatment; Adult; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Chronic Disease; chronic migraine; Data processing; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Headaches; Humans; Longitudinal Studies; Male; Middle Aged; migraine; Migraine Disorders - chemically induced; Migraine Disorders - drug therapy; Migraine Disorders - epidemiology; migraine progression; nonsteroidal anti-inflammatory drug; Nonsteroidal anti-inflammatory drugs; Piperidines - adverse effects; Piperidines - therapeutic use; Population Surveillance - methods; Prevalence; Quality of life; Serotonin 5-HT1 Receptor Agonists - adverse effects; Serotonin 5-HT1 Receptor Agonists - therapeutic use; Sumatriptan - adverse effects; Sumatriptan - therapeutic use; triptan; Tryptamines - adverse effects; Tryptamines - therapeutic use; United States - epidemiology; migraine progression; migraine; triptan; chronic migraine; acute treatment; nonsteroidal anti-inflammatory drug

Objectives To assess the influence of triptan or nonsteroidal anti‐inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). Background CM is common in tertiary headache care, and relative to EM, CM is associated with a number of d...